Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2007

View Archived Issues

AN-2690 study results encouraging

Case studies demonstrate activity of efalizumab in dermatologic diseases

Dimericine(TM) may ameliorate UVB-induced DNA damage

Snapshots from the 2007 Gastrointestinal Cancers Symposium: Part II

NF-kappaB inhibitors inhibit Abeta production in vitro: potential efficacy in AD

Target enrollment reached in phase III study of Bronchitol in bronchiectasis

South American studies planned for RPI-MN

Novel activation mechanism for the pain-sensing TRPA1 channel / News in Context

ZEN-012 active against a variety of tumors in vivo

Zonisamide effective against binge eating, although not well tolerated

Novel immunomodulatory agents disclosed in recent Kyorin and Novartis patents

Recent Isis and Louisiana State University patents report novel diagnostic agents

Recent patents impart new therapeutic agents for cancer

Biofusion launches Absynth Biologics

Novel prepandemic H5N1 vaccine filed in Japan

New phase II trial for prostaglandin derivative JB-991

New dosing recommendations for Rapamune in high immunologic risk patients

ProMetic BioSciences: pipeline status

CytoDyn acquires UTEK subsidiary

SciClone plans phase II study of SCV-07

Treatment begins in Cytori's adipose stem cell trial

Phase III Prochieve study for prevention of preterm birth fails to meet endpoints

Wyeth and Medivas collaborate to develop advanced hemophilia treatments

First pivotal obesity study of lorcaserin completes enrollment

Treatment completed in phase III trials of Miraxion in Huntington's disease

Cambrex shareholders approve sale of bio businesses to Lonza

Sequential schedule of docetaxel/gemcitabine shows promising activity in MBC

Meta-analysis finds trastuzumab to increase cardiotoxicity and brain metastasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...